cetrorelix


Also found in: Wikipedia.

cetrorelix

 [set″ro-rel´iks]
a gonadotropin-releasing hormone antagonist, used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian stimulation during infertility treatment; administered subcutaneously.

cetrorelix

/cet·ro·rel·ix/ (set″ro-rel´iks) a gonadotropin-releasing hormone antagonist, used as the acetate salt to inhibit premature surges of luteinizing hormone in women undergoing controlled ovarian stimulation during infertility treatment.

cetrorelix

[set′rorel′iks]
a gonadotropin-releasing hormone antagonist used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian stimulation during infertility treatment, administered subcutaneously.
References in periodicals archive ?
In Group A patients, when the leading follicle reached a size of 14 mm, GnRH antagonist Cetrorelix was added and continued along with HMG daily till the day of h CG.
25 mg cetrorelix (Cetrotide; Asta Medica, Frankfurt, Germany) was administered daily when two or more follicles reached 13-14 mm in diameter.
When the leading follicle reached the size of 14 mm and/or the levels of estradiol reached the value >300 pg/mL, a daily injection of cetrorelix 0.
Antagonist Cetrorelix (Merk-Sereno, Geneva, Switzerland) 0.
GnRH antagonist fixed protocol included direct gonadotropin suppression via the subcutaneous administration of cetrorelix acetate (Cetrotide 0.
Ganirelix (Ganirelix) and cetrorelix (Cetrotide) are GnRH antagonists similar in structure to GNRH.
Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies.
The second group (N=501) included all patients during the same period who did not have a diagnosis of PCOS but did require controlled ovulation induction using a cetrorelix regimen (cetrorelix-non-PCOS group).
Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
25 mg of the GnRH antagonist cetrorelix (Cetrotide) or a midluteal daily injection of 0.
Pais-sede do Medicamento fabricante Classificacao Anvisa ACETATO DE CASPOFUNGINA EUA Entidade molecular nova 50mg po liof inj ACETATO DE CETRORELIX Suica Entidade molecular nova 0,25mg po liof inj ACETATO DE GANIRELIX Holanda Entidade molecular nova 0,5mg/ml sol inj AMOXICILINA 1.
En otro trabajo experimental, el agonista de GnRH cetrorelix redujo la apoptosis en las celulas de la granulosa, al inhibir la apoptosis dependiente de mitocondrias que es acelerada por la quimioterapia (63).